Backed by ASCO data Arcus guns for phase 3
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Nuvation gets in before Nuvalent
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
